This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Infectious disease				
HIV/AIDS	Not applicable	<p><i>In vitro</i> studies suggest inducing an IgG3 response against HIV antigens could help create protective immunity against infection. In a clinical trial, Sanofi's ALVAC HIV vaccine and a bivalent clade B/E recombinant gp120 immunogen induced an antigen-specific IgG3 response and partial protective immunity, whereas another vaccination regimen that induced a weaker IgG3 response did not result in protective immunity. Next steps could include developing a vaccination strategy that induces a persistent IgG3 response.</p> <p>ALVAC HIV is in Phase III testing.</p> <p>SciBX 7(17); doi:10.1038/scibx.2014.496 Published online May 1, 2014</p>	Patent and licensing status unavailable	<p>Yates, N.L. <i>et al. Sci. Transl. Med.</i>; published online March 19, 2014; doi:10.1126/scitranslmed.3007730</p> <p>Contact: Georgia D. Tomaras, Duke University, Durham, N.C. e-mail: gdt@duke.edu</p>